Poster 522 Peripheral Edema and Weight Gain in Adult Patients with Painful Diabetic Peripheral Neuropathy (DPN) Receiving Gabapentin Enacarbil (GEn) or Pregabalin Enrolled in a Randomized Phase 2 Trial

Calkins, Anne; Shurman, Joseph; Jaros, Mark; Kim, Richard; Shang, Gwendoline

doi:10.1016/j.pmrj.2014.08.890

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastrointestinal adverse effects such as abdominal distension, abnormal appetite, constipation, dry mouth and nausea are common and are dose-related with the exception of constipation. 38,42 Peripheral oedema can affect 17% of all patients treated with pregabalin 48 and has been associated with the development of heart failure in case reports. 49 However, a large cohort study did not find an increased risk of heart failure with pregabalin as compared to gabapentin.…”

Section: Gastrointestinal Effectsmentioning

confidence: 99%

Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice

Chincholkar

2020

British Journal of Pain

View full text Add to dashboard Cite

The gabapentinoids are often recommended as first-line treatments for the management of neuropathic pain. The differing pharmacodynamic and pharmacokinetic profiles can have implications for clinical practice. This article has summarised these key differences. In addition to their use in managing neuropathic pain, gabapentinoids are increasingly being used for off-label conditions despite the lack of evidence. Prescription rates for off-label conditions have overtaken that for on-label use. Similarly, the use of gabapentinoids in the perioperative period is now embedded in clinical practice despite conflicting evidence. This article summarises the risks associated with this increasing use. There is increasing evidence of the potential to cause harm in vulnerable populations such as the elderly and increasing prevalence of abuse. The risk of respiratory depression in combination with opioids is of particular concern in the context of the current opioid crisis. This article describes the practical considerations involved that might help guide appropriate prescribing practices.

show abstract

Section: Gastrointestinal Effectsmentioning

confidence: 99%

Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice

Chincholkar

2020

British Journal of Pain

View full text Add to dashboard Cite

show abstract

Poster 522 Peripheral Edema and Weight Gain in Adult Patients with Painful Diabetic Peripheral Neuropathy (DPN) Receiving Gabapentin Enacarbil (GEn) or Pregabalin Enrolled in a Randomized Phase 2 Trial

Cited by 1 publication

References 0 publications

Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice

Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice

Contact Info

Product

Resources

About